Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate

J Miller, TH TarterSouthern Illinois University School of Medicine, Department of Surgery, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prost...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	J Miller, TH Tarter
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	prostatic hyperplasia 5-reductase inhibitor dutasteride tamsulosin Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/d74f0e46ff1443e5b74c41b7fcd4a63e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d74f0e46ff1443e5b74c41b7fcd4a63e
record_format	dspace
spelling	oai:doaj.org-article:d74f0e46ff1443e5b74c41b7fcd4a63e2021-12-02T00:36:30ZCombination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate1178-1998https://doaj.org/article/d74f0e46ff1443e5b74c41b7fcd4a63e2009-06-01T00:00:00Zhttps://www.dovepress.com/combination-therapy-with-dutasteride-and-tamsulosin-for-the-treatment--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998J Miller, TH TarterSouthern Illinois University School of Medicine, Department of Surgery, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. Interim results of the ongoing Combination of Avodart and Tamsulosin (CombAt) study have shown combination therapy with the 5α-reductase inhibitor dutasteride and the α1-adrenergic antagonist tamsulosin offer significant improvements from baseline compared with either drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasteride, tamsulosinJ MillerTH TarterDove Medical Pressarticleprostatic hyperplasia5-reductase inhibitordutasteridetamsulosinGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 251-258 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostatic hyperplasia 5-reductase inhibitor dutasteride tamsulosin Geriatrics RC952-954.6
spellingShingle	prostatic hyperplasia 5-reductase inhibitor dutasteride tamsulosin Geriatrics RC952-954.6 J Miller TH Tarter Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
description	J Miller, TH TarterSouthern Illinois University School of Medicine, Department of Surgery, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. Interim results of the ongoing Combination of Avodart and Tamsulosin (CombAt) study have shown combination therapy with the 5α-reductase inhibitor dutasteride and the α1-adrenergic antagonist tamsulosin offer significant improvements from baseline compared with either drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasteride, tamsulosin
format	article
author	J Miller TH Tarter
author_facet	J Miller TH Tarter
author_sort	J Miller
title	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
title_short	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
title_full	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
title_fullStr	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
title_full_unstemmed	Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
title_sort	combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/d74f0e46ff1443e5b74c41b7fcd4a63e
work_keys_str_mv	AT jmiller combinationtherapywithdutasterideandtamsulosinforthetreatmentofsymptomaticenlargedprostate AT thtarter combinationtherapywithdutasterideandtamsulosinforthetreatmentofsymptomaticenlargedprostate
_version_	1718403648639205376

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate

Ejemplares similares